We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Photodynamic Therapy of Acne Vulgaris - a Randomized Blinded Controlled Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00206895
First Posted: September 21, 2005
Last Update Posted: October 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
  Purpose
The purpose of the study is to evaluated the efficacy and tolerability of methyl aminolevulinate and 5-aminolevulinic acid photodynamic therapy in patients with moderate to severe facial acne vulgaris in a randomized controlled and investigator blinded trial.

Condition Intervention
Acne Vulgaris Procedure: Photodynamic therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • Lesion counts (non-inflammatory and inflammatory)
  • Leeds Revised Acne Grading System

Secondary Outcome Measures:
  • Pain
  • Side effects

Estimated Enrollment: 24
Study Start Date: November 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:18 years or older, good health, more than 12 inflammatory facial acne lesions -

Exclusion Criteria:skin type VI, pregnant or lactating woman. Oral retinoid use within one year, systemic antibiotics within 1 month, topical acne treatment within 2 weeks.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00206895


Locations
Denmark
Bispebjerg Hospital
Copenhagen, Copenhagen NV, Denmark, 2400
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
Study Director: Hans Christian Wulf, MD, Sci Bispebjerg Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00206895     History of Changes
Other Study ID Numbers: KF-01-177/04
First Submitted: September 12, 2005
First Posted: September 21, 2005
Last Update Posted: October 11, 2006
Last Verified: October 2004

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases